237 related articles for article (PubMed ID: 31015807)
21. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.
Marzi A; Feldmann F; Geisbert TW; Feldmann H; Safronetz D
Emerg Infect Dis; 2015 Feb; 21(2):305-7. PubMed ID: 25625358
[TBL] [Abstract][Full Text] [Related]
22. Immunobiology of Ebola and Lassa virus infections.
Prescott JB; Marzi A; Safronetz D; Robertson SJ; Feldmann H; Best SM
Nat Rev Immunol; 2017 Mar; 17(3):195-207. PubMed ID: 28111475
[TBL] [Abstract][Full Text] [Related]
23. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.
Cashman KA; Wilkinson ER; Shaia CI; Facemire PR; Bell TM; Bearss JJ; Shamblin JD; Wollen SE; Broderick KE; Sardesai NY; Schmaljohn CS
Hum Vaccin Immunother; 2017 Dec; 13(12):2902-2911. PubMed ID: 29045192
[TBL] [Abstract][Full Text] [Related]
24. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS
Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337
[TBL] [Abstract][Full Text] [Related]
25. Development of a new vaccine for the prevention of Lassa fever.
Geisbert TW; Jones S; Fritz EA; Shurtleff AC; Geisbert JB; Liebscher R; Grolla A; Ströher U; Fernando L; Daddario KM; Guttieri MC; Mothé BR; Larsen T; Hensley LE; Jahrling PB; Feldmann H
PLoS Med; 2005 Jun; 2(6):e183. PubMed ID: 15971954
[TBL] [Abstract][Full Text] [Related]
26. Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development.
Ibukun FI
Viruses; 2020 Mar; 12(4):. PubMed ID: 32244402
[TBL] [Abstract][Full Text] [Related]
27. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens.
Fathi A; Dahlke C; Addo MM
Hum Vaccin Immunother; 2019; 15(10):2269-2285. PubMed ID: 31368826
[TBL] [Abstract][Full Text] [Related]
28. Towards a human Lassa fever vaccine.
Fisher-Hoch SP; McCormick JB
Rev Med Virol; 2001; 11(5):331-41. PubMed ID: 11590670
[TBL] [Abstract][Full Text] [Related]
29. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
[TBL] [Abstract][Full Text] [Related]
30. Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria.
Ugwu C; Olumade T; Nwakpakpa E; Onyia V; Odeh E; Duruiheoma RO; Ojide CK; Eke MA; Nwafor IE; Chika-Igwenyi N; Abu AM; Azuogu B; Ajayi N; Ogah E; Ayodeji O; Abejegah C; Adedosu N; Oyejide N; Abah S; Omidele A; Ingbian W; Osoba E; Eromon P; Oluniyi P; Ogunsanya O; Happi A; Otuh P; Nadesalingam A; Carnell G; Krause N; Aguinam E; Kinsley R; Storisteanu DML; Tonks P; Nelson D; McAlister C; Boisen M; Garry R; Wright E; Temperton N; Frost S; Heeney JL; Happi C
Sci Rep; 2022 Dec; 12(1):22330. PubMed ID: 36567369
[TBL] [Abstract][Full Text] [Related]
31. Lassa Virus Replicon Particle Vaccine Protects Strain 13/N Guinea Pigs Against Challenge With Geographically and Genetically Diverse Viral Strains.
Spengler JR; Kainulainen MH; Welch SR; Coleman-McCray JD; Harmon JR; Condrey JA; Scholte FEM; Nichol ST; Montgomery JM; Albariño CG; Spiropoulou CF
J Infect Dis; 2022 Nov; 226(9):1545-1550. PubMed ID: 35099012
[TBL] [Abstract][Full Text] [Related]
32. Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate.
Zapata JC; Carrion R; Patterson JL; Crasta O; Zhang Y; Mani S; Jett M; Poonia B; Djavani M; White DM; Lukashevich IS; Salvato MS
PLoS Negl Trop Dis; 2013; 7(9):e2406. PubMed ID: 24069471
[TBL] [Abstract][Full Text] [Related]
33. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge.
Fischer RJ; Purushotham JN; van Doremalen N; Sebastian S; Meade-White K; Cordova K; Letko M; Jeremiah Matson M; Feldmann F; Haddock E; LaCasse R; Saturday G; Lambe T; Gilbert SC; Munster VJ
NPJ Vaccines; 2021 Mar; 6(1):32. PubMed ID: 33654106
[TBL] [Abstract][Full Text] [Related]
34. Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis.
Oppliger J; Torriani G; Herrador A; Kunz S
J Virol; 2016 Jul; 90(14):6412-6429. PubMed ID: 27147735
[TBL] [Abstract][Full Text] [Related]
35. Mutational Analysis of Lassa Virus Glycoprotein Highlights Regions Required for Alpha-Dystroglycan Utilization.
Acciani M; Alston JT; Zhao G; Reynolds H; Ali AM; Xu B; Brindley MA
J Virol; 2017 Sep; 91(18):. PubMed ID: 28679759
[TBL] [Abstract][Full Text] [Related]
36. Immune-Mediated Systemic Vasculitis as the Proposed Cause of Sudden-Onset Sensorineural Hearing Loss following Lassa Virus Exposure in Cynomolgus Macaques.
Cashman KA; Wilkinson ER; Zeng X; Cardile AP; Facemire PR; Bell TM; Bearss JJ; Shaia CI; Schmaljohn CS
mBio; 2018 Oct; 9(5):. PubMed ID: 30377282
[TBL] [Abstract][Full Text] [Related]
37. Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein.
Galan-Navarro C; Rincon-Restrepo M; Zimmer G; Ollmann Saphire E; Hubbell JA; Hirosue S; Swartz MA; Kunz S
Virology; 2017 Dec; 512():161-171. PubMed ID: 28963882
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic applications for Lassa fever in limited-resource settings.
Emperador DM; Yimer SA; Mazzola LT; Norheim G; Kelly-Cirino C
BMJ Glob Health; 2019; 4(Suppl 2):e001119. PubMed ID: 30899576
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
[TBL] [Abstract][Full Text] [Related]
40. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.
Leblanc P; Moise L; Luza C; Chantaralawan K; Lezeau L; Yuan J; Field M; Richer D; Boyle C; Martin WD; Fishman JB; Berg EA; Baker D; Zeigler B; Mais DE; Taylor W; Coleman R; Warren HS; Gelfand JA; De Groot AS; Brauns T; Poznansky MC
Hum Vaccin Immunother; 2014; 10(10):3022-38. PubMed ID: 25483693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
